US markets have been very lucrative for the Indian pharma companies and many companies such as Ranbaxy and Dr Reddy's capitalised on this opportunity.
Research and development (R&D) spending by BSE 100 companies has grown steadily, rising from 0.89 per cent of revenue in FY20 to 1.32 per cent in FY24, averaging around 1 per cent over the period in-between, according to data compiled from Bloomberg and company annual reports. Also, these companies more than doubled their R&D spending in absolute terms over these five years: From Rs 25,041 crore to Rs 63,072 crore. While this reflects a prioritisation of innovation, corporate R&D investment remains relatively conservative.
What makes Pushpa 2 float is Allu Arjun's magnetic performance. The actor really goes an extra mile to deliver the wildfire he promised, observes Mayur Sanap.
Ask rediffGURU and PF and MF expert Janak Patel your mutual fund and personal finance-related questions.
Arjun Menon looks at the Top 10 South films that made an impact in 2024.
The BCG analysis shows Lupin gave an annualised average TSR of 29.9 per cent, ahead of the 18.4 per cent of Israel-based Teva Pharmaceutical, the world's largest generics maker. Teva is next on the list. Another Indian generic maker, Glenmark, occupies third position, with an 18 per cent TSR to its investors.
The company has entered into a tie-up with the US-based FSC Laboratories as its authorised generic partner for FSC's hypertension medicine Isoptin SR (Verapamil SR) in the US.
Watch her in hand-to-hand combat, wielding guns, firing weapons and breaking bones like a beast in some of the sleekly done one-take sequences. She also owns some emotionally-charged moments within the same dramatic beat, observes Mayur Sanap.
Closure would mean manufacturer might not be able to launch any new generic products in India in future.
Banerjee had on Wednesday said an amendment to existing laws will be passed in the state assembly next week to ensure capital punishment to convicted rapists.
'API prices are dragging down margins and impacting our competitive ability.'
The pharmaceuticals sector is expected to post a revenue growth of around 13.5 per cent and a net profit growth of 30.3 per cent for the third quarter of 2023-24 (FY24), riding on the approval for niche drugs in the US market, fall in raw material prices and correction in shipping rates. In the healthcare segment, hospitals are expected to post revenue growth of 13 per cent during the coverage, while net profit growth would be around 37 per cent, ICICI Securities said in a note. However, the performance may not be comparable on a sequential basis due to the offset of the festive season in Q3FY24, the analysts noted.
Amaran is effective as a intimate, well researched piece of storytelling but does not try to break any new ground, observes Arjun Menon.
USFDA has extended the timeline for granting tentative approval to generic drug applications filed under Para IV of its rules by 10 months.
'There is no reason why we should break this business up.'
Most of the pharma units are failing in documentation, and validation processes, and many don't have full-fledged quality control laboratories.
Charging the multinational companies with making several drugs beyond the reach of the poor, visiting Commerce Minister Anand Sharma today asserted it is the Indian generics which have challenged such a "suffocating stranglehold" and made the medicines affordable.
If you're a fan of the Transformer films already, you will be delighted with a hearty dose of nostalgia here but... Mayur Sanap adds a caveat.
Regulator says fee would enable it to quicken approval process.
Devara's self-appointed guardian of the sea unleashing violence as a means to end violence is purely Junior NTR fan-tasy, observes Sukanya Verma.
Generic drugmakers cannot be sued under state law for adverse reactions to their products.
'There is not any negative connotation associated with it.'
Continued demand for generics from the US market will ensure stable outlook for Indian Generics Pharmaceuticals in 2011, global rating agency Fitch Ratings said on Monday.
India's biggest drug maker Ranbaxy Laboratories Ltd has put in its bid to acquire generic business of German pharmaceutical firm Merck.
'Whichever company offers better incentives, the chemist would prefer it.'
The drug that it would supply is called Olanzapine, used to treat schizophrenia and bipolar disorder.
Mandatory prescription of generic names is not a complete solution. Rather, in the absence of a range of approaches, it could mean passing the choice of selecting a drug from a doctor to a pharmacist, says Chandrakant Lahariya.
Washington-based Pharmaceutical Research and Manufacturers of America (PhRMA), the representative body of US-based drug firms, has said it does not support the seizure of legitimate generic medicines meant for developing country destinations.
Sarfira seems to be scene-to-scene copy of the original, which begs the question: Why re-do a film if there's nothing new to add, asks Mayur Sanap.
GlaxoSmithKline Plc's anti-migraine drug brand, Imitrex, is turning out to be a good revenue earner for Indian generic companies.
Dr Reddy's Laboratories has succeeded in developing a copycat or generic version of Pfizer's Lipitor, the world's largest selling drug which has sales of over $10 billion.
Favivir is the second drug developed by Hetero after Covifor (Remdesivir) used in the treatment of COVID-19.
The launch came after final approval from the US health regulator to manufacture the generic version of Lipitor at Ranbaxy's wholly owned Ohm Laboratories facility in New Brunswick, New Jersey, as well as market the product.
'However, we have seen weakness in our active pharmaceutical ingredients business.'
The US market for the drug is pegged at $1 billion. Cipla has been selling the product in the European market. It had won a similar case in the UK against GSK a couple of years ago.
Even smaller companies like Torrent Pharma and Alembic file five to 10 ANDAs every year.
© 2026 Rediff.com - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances